[go: up one dir, main page]

IE894111L - Phosphinic acid substituted steroids as inhibitors of¹steroid 5ó-reductase - Google Patents

Phosphinic acid substituted steroids as inhibitors of¹steroid 5ó-reductase

Info

Publication number
IE894111L
IE894111L IE894111A IE411189A IE894111L IE 894111 L IE894111 L IE 894111L IE 894111 A IE894111 A IE 894111A IE 411189 A IE411189 A IE 411189A IE 894111 L IE894111 L IE 894111L
Authority
IE
Ireland
Prior art keywords
reductase
inhibitors
of1steroid
phosphinic acid
acid substituted
Prior art date
Application number
IE894111A
Original Assignee
Bryant & May Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bryant & May Ltd filed Critical Bryant & May Ltd
Publication of IE894111L publication Critical patent/IE894111L/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J63/00—Steroids in which the cyclopenta(a)hydrophenanthrene skeleton has been modified by expansion of only one ring by one or two atoms
    • C07J63/002—Expansion of ring A by one atom, e.g. A homo steroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J51/00—Normal steroids with unmodified cyclopenta(a)hydrophenanthrene skeleton not provided for in groups C07J1/00 - C07J43/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J61/00—Steroids in which the cyclopenta(a)hydrophenanthrene skeleton has been modified by contraction of only one ring by one or two atoms

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Urology & Nephrology (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Steroid Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

Compounds of structure (I) <CHEM> in which the dotted lines indicate the optional presence of double bonds and, inter alia, R<1> is H, R<2> is H or CH3 and R<3> is H, hydroxy or acetoxy; processes for their preparation, pharmaceutical compositions containing them and their use in medicine as inhibitors of 5- alpha -reductase. [EP0375349A1]
IE894111A 1988-12-23 1989-12-20 Phosphinic acid substituted steroids as inhibitors of¹steroid 5ó-reductase IE894111L (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US07/290,212 US5026882A (en) 1988-12-23 1988-12-23 Phosphinic acid substituted steroids as inhibitors of steroid 5α-reductase

Publications (1)

Publication Number Publication Date
IE894111L true IE894111L (en) 1990-06-23

Family

ID=23114995

Family Applications (1)

Application Number Title Priority Date Filing Date
IE894111A IE894111L (en) 1988-12-23 1989-12-20 Phosphinic acid substituted steroids as inhibitors of¹steroid 5ó-reductase

Country Status (13)

Country Link
US (1) US5026882A (en)
EP (1) EP0375349B1 (en)
JP (1) JPH02215796A (en)
AT (1) ATE110735T1 (en)
AU (1) AU630139B2 (en)
CA (1) CA2005214A1 (en)
DE (1) DE68917884T2 (en)
DK (1) DK645389A (en)
ES (1) ES2059789T3 (en)
HU (1) HU205137B (en)
IE (1) IE894111L (en)
PT (1) PT92723A (en)
ZA (1) ZA899671B (en)

Families Citing this family (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5571817A (en) * 1984-02-27 1996-11-05 Merck & Co., Inc. Methods of treating androgenic alopecia with finasteride [17β-N-mono-substituted-carbamoyl-4-aza-5-α-androst-1-en-ones]
US5138063A (en) * 1984-02-27 1992-08-11 Merck & Co., Inc. 17β-methoxycarbonyl-4-aza-androsten-1-en-3-ones
US4882319A (en) * 1988-12-23 1989-11-21 Smithkline Beckman Corporation Phosphonic acid substituted aromatic steroids as inhibitors of steroid 5-α-reductase
US4970204A (en) * 1989-08-23 1990-11-13 Smithkline Beecham Corporation 3-substituted nitro-steroid derivatives as 5-α-reductase inhibitors
US5516768A (en) * 1990-03-16 1996-05-14 Smithkline Beecham Corporation Uncompetitive inhibition of steroid and 5α-reductose
US5061802A (en) * 1990-06-20 1991-10-29 Merck & Co. Inc. 17β-aminobenzoyl-4-aza-5α-androst-1-en-3-ones as benign prostatic hypertrophy agents
US5162332A (en) * 1990-06-20 1992-11-10 Merck & Co., Inc. Selected 17 β-polyaroyl-4-aza-5 α-androst-1-en-3-ones as steroidal reductase inhibitors
US5098908A (en) * 1990-06-20 1992-03-24 Merck & Co., Inc. 17β-hydroxybenzoyl-4-aza-5α-androst-1-en-3-ones as testosterone reductase inhibitors
US5151430A (en) * 1990-06-20 1992-09-29 Merck & Co., Inc. Specific 17β-thiobenzoyl-4-aza-5α-androst-1-en-3-ones as antiandrogen agents
US5091380A (en) * 1990-06-28 1992-02-25 Merck & Co., Inc. N-monosubstituted adamantyl/norbornanyl 17β-carbamides of 3-carboxy-androst-3,5-dienes as testosterone 5α-reductase inhibitors
CH681153A5 (en) * 1991-01-28 1993-01-29 Marigen S.A. New and sterolester- sterolphosphorverbindungen.
NZ241979A (en) * 1991-03-20 1996-01-26 Merck & Co Inc Treatment of benign prostatic hyperplasia using 5alpha-reductase inhibitor and an alpha1-adrenergic recepter blocker
CA2135174A1 (en) * 1992-05-20 1993-11-25 Gary H. Rasmusson 17-ethers and thioethers of 4-aza-steroids
EP0649306B1 (en) * 1992-05-20 2001-01-10 Merck & Co. Inc. Ester derivatives of 4-aza-steroids
CA2135055A1 (en) * 1992-05-20 1993-11-25 Bruce E. Witzel 4-azasteroid 5-alpha-reductase inhibitors
US5237064A (en) * 1992-05-20 1993-08-17 Merck & Co., Inc. Process for producing 7β-substituted-aza-5αandrostan-3-ones
JPH07508034A (en) * 1992-05-20 1995-09-07 メルク　エンド　カンパニー　インコーポレーテッド 17-amino substituted 4-azasteroid 5α-reductase inhibitor
RU94046044A (en) * 1992-05-20 1996-10-10 Мерк Энд Ко. NEW 7β-SUBSTITUTED 4-AZA-5a-CHOLESTAN-ONES AS INHIBITORS OF 5a-REDUCTASE, PHARMACEUTICAL COMPOSITION BASED ON THEREOF, METHOD OF ITS PREPARING
WO1993023420A1 (en) * 1992-05-20 1993-11-25 Merck & Co., Inc. NEW 7β-SUBSTITUTED-4-AZA-5α-ANDROSTAN-3-ONES AS 5α-REDUCTASE INHIBITORS
SK140494A3 (en) * 1992-05-21 1995-07-11 Endorecherche Inc Inhibitors of testosterone 5-alpha-reductase activity
US5324734A (en) * 1992-09-15 1994-06-28 Merck & Co., Inc. Oxidization metabolites of 5-α-23-methyl-4-aza-21-nor-chol-1-ene-3, 20-dione
US5278159A (en) * 1992-10-06 1994-01-11 Merck & Co., Inc. Aryl ester derivatives of 3-oxo-4-aza-androstane 17-β-carboxylates as 5-α-reductase inhibitors
US5359071A (en) * 1993-03-12 1994-10-25 Merck & Co., Inc. 15-substituted 4-azasteroids
WO1994021614A1 (en) * 1993-03-24 1994-09-29 Merck & Co., Inc. SUBSTITUTED 3-PHENANTHRIDINONE DERIVATIVES AS 5α-REDUCTASE INHIBITORS
AU679769B2 (en) * 1993-06-28 1997-07-10 Merck & Co., Inc. 4-AZA-pregnane 5alpha-reductase isozyme 1 inhibitors
TW369521B (en) * 1993-09-17 1999-09-11 Smithkline Beecham Corp Androstenone derivative
US5541322A (en) * 1994-10-14 1996-07-30 Glaxo Wellcome Inc. Synthesis of 6-azaandrostenones
US6867216B1 (en) 1998-04-09 2005-03-15 Johns Hopkins University School Of Medicine Inhibitors of hedgehog signal pathways, compositions and uses related thereto
IL138645A0 (en) * 1998-04-09 2001-10-31 Univ Johns Hopkins Med Use of steroidal alkaloid derivatives as inhibitors of hedghog signalling pathways
US7291626B1 (en) 1998-04-09 2007-11-06 John Hopkins University School Of Medicine Inhibitors of hedgehog signaling pathways, compositions and uses related thereto
ES2347027T3 (en) 1998-05-22 2010-10-22 The Board Of Trustees Of The Leland Stanford Junior University BIFUNCTIONAL MOLECULES AND THERAPIES BASED ON THE SAME.
CA2386190C (en) 1999-10-13 2009-04-14 Johns Hopkins University School Of Medicine Regulators of the hedgehog pathway, compositions and uses related thereto
DK1889198T3 (en) 2005-04-28 2015-02-09 Proteus Digital Health Inc Pharma-informatics system
JP2009508494A (en) 2005-09-16 2009-03-05 ラプトール ファーマシューティカル インコーポレイテッド Compositions comprising receptor-binding protein (RAP) variants specific for proteins comprising CR and uses thereof
NZ594310A (en) 2009-02-20 2014-02-28 To Bbb Holding B V Glutathione-based drug delivery system
KR20180114970A (en) 2009-05-06 2018-10-19 라보라토리 스킨 케어, 인크. Dermal delivery compositions comprising active agent-calcium phosphate particle complexes and methods of using the same

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4191759A (en) * 1978-04-13 1980-03-04 Merck & Co., Inc. N-substituted-17β-carbamoylandrost-4-en-3-one 5α reductase inhibitors
US4377584A (en) * 1978-04-13 1983-03-22 Merck & Co., Inc. 4-Aza-17β-substituted-5α-androstan-3-one-reductase inhibitors
US4317817A (en) * 1979-08-27 1982-03-02 Richardson-Merrell Inc. Novel steroid 5α-reductase inhibitors
DK465481A (en) * 1980-11-21 1982-05-22 Hoffmann La Roche PROCEDURE FOR THE MANUFACTURE OF D-HOMOSTOMOIDS
CA1252778A (en) * 1983-08-25 1989-04-18 Hoffmann-La Roche Limited/Hoffmann-La Roche Limitee Steroids
US4910226A (en) * 1987-04-29 1990-03-20 Smithkline Beckman Corporation Steroid 5-alpha-reductase inhibitors
US4946834A (en) * 1988-12-23 1990-08-07 Smithkline Beecham Corporation Phosphonic acid substituted steroids as steroid 5α-reductase inhibitors
US4937237A (en) * 1988-12-23 1990-06-26 Smithkline Beckman Corporation Phosphinic acid substituted aromatic steroids as inhibitors of steroid 5-60 -reductase
US4882319A (en) * 1988-12-23 1989-11-21 Smithkline Beckman Corporation Phosphonic acid substituted aromatic steroids as inhibitors of steroid 5-α-reductase

Also Published As

Publication number Publication date
HU205137B (en) 1992-03-30
US5026882A (en) 1991-06-25
AU630139B2 (en) 1992-10-22
ZA899671B (en) 1990-11-28
JPH02215796A (en) 1990-08-28
DK645389A (en) 1990-06-24
ATE110735T1 (en) 1994-09-15
PT92723A (en) 1990-06-29
EP0375349A1 (en) 1990-06-27
DE68917884D1 (en) 1994-10-06
CA2005214A1 (en) 1990-06-23
DE68917884T2 (en) 1995-03-23
HU895286D0 (en) 1990-01-28
EP0375349B1 (en) 1994-08-31
ES2059789T3 (en) 1994-11-16
DK645389D0 (en) 1989-12-19
HUT55795A (en) 1991-06-28
AU4703989A (en) 1990-06-28

Similar Documents

Publication Publication Date Title
IE894111L (en) Phosphinic acid substituted steroids as inhibitors of¹steroid 5ó-reductase
IE881269L (en) Steroids
AU4699589A (en) Phosphonic acid substituted aromatic steroids as inhibitors of steroid 5 alpha-reductase
AU1077888A (en) Steroid 5-alpha-reductase inhibitors
AU4700389A (en) Phosphonic acid substituted steroids as steroid 5alpha- reductase inhibitors
AU4700489A (en) Phosphinic acid substituted aromatic steroids as inhibitors of steriod 5alpha-reductase
IL86464A (en) 4-phosphinyl-3- hydroxybutanoic acid derivatives useful as cholesterol biosynthesis inhibitors and pharmaceutical compositions containing the same
ES8603870A1 (en) Derivatives of 2,2&#39;-iminobisethanol.
AU4700589A (en) Sulfonic acid substituted aromatic steroids as inhibitors of steroids 5 alpha-reductase
IE862404L (en) Hydroxamic acid derivatives
AU641701B2 (en) 11-keto or hydroxy 3,5-diene steroids as inhibitors of steroid 5-alpha-reductase
AU640396B2 (en) 7-keto or hydroxy 3,5-diene steroids as inhibitors of steroid 5-alpha-reductase
AU5988086A (en) New carboxylic acid derivatives, processes for the preparation thereof, the use thereof and pharmaceutical compositions containing them
IE45439L (en) Penicillanic acid derivatives
AU642434B2 (en) New intermediates of pyridone, process and intermediates of preparation,their application as medicaments and compositions containing them
EP0347932A3 (en) Treatment of conditions requiring enhanced oxygen availability to mammalian tissues
HU895952D0 (en) Process for the preparation of substituted pyrrolidone-2-carboxylic acid derivatives and pharmaceutical compositions containing them
AU7329687A (en) Steroids useful as anti-cancer and anti-obesity agents
AU7066287A (en) Pharmaceutical compositions containing 5-phenyl-1, 3-dioxoalkenyl compounds
EP0124252A3 (en) Double ester of 16beta-ethylestran-17beta-ol derivatives
FR2627487B1 (en) NEW DERIVATIVE OF VALPROIC ACID, PROCESS FOR THE PREPARATION OF THIS COMPOUND AND THE ANTIPLEPTIC MEDICINE CONTAINING THE SAME
SE9601483D0 (en) Preparation of composition
JPS5219693A (en) Preparation of novel 7alpha-methoxycephalosporin derivatives